Biogen's stock struggles to surpass its $206 resistance level despite the company's acquisition of Apellis and strong sales growth of its Alzheimer's drug Leqembi, which saw a 75% year-over-year increase to $168 million in Q1 2026. However, skepticism remains due to declining sales of its other key drugs Tecfidera, Avonex, and Spinraza, which fell 18.8% year-over-year to $646.7 million in the same quarter. These mixed results have led to a downgrade of Biogen's stock rating to Hold, reflecting concerns about its overall commercial prospects despite leadership in the Alzheimer's therapeutics market in Japan and the U.S.
Biogen Inc. announced the appointment of Michael J. Parini as its new Chief Legal Officer, effective August 3, 2026. Parini brings over 20 years of legal and strategic leadership in the biopharmaceutical industry, having held senior roles at Spur The...
The LEADER study found that nearly 83% of early Alzheimer's patients remained stable or improved while on LEQEMBI treatment for an average of 17 months, consistent across demographics and genetic profiles. LEQEMBI targets amyloid beta to slow cogniti...
Biogen announced positive Phase 2 results for diranersen, an antisense therapy targeting tau protein in early Alzheimer's disease. The study showed meaningful clinical benefits, including slowing cognitive decline by up to 50% on some measures, and r...
The FDA has approved LEQEMBI IQLIK, a once-weekly subcutaneous injection for initiating treatment of early Alzheimer's disease, allowing at-home dosing. This new form offers a convenient alternative to intravenous infusions, providing flexibility for...
Biogen's stock received an upgrade as investors anticipate the company's upcoming announcement of detailed data from its Phase 2 study on an experimental Alzheimer's drug. This data release is significant because it could impact the future of Alzheim...
